IceCure Medical Advances Cryoablation Technology with Patent Approval and Regulatory Clearance for XSense System
核心洞察
IceCure Medical received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation XSense cryoprobe technology designed to reduce tissue trauma during tumor extraction.
The company's XSense System has obtained regulatory approval in Israel for broad indications including breast cancer, gynecology, and oncology, following earlier FDA clearance in the United States.
The liquid-nitrogen-based cryoablation platform offers a minimally invasive alternative to surgical tumor removal, potentially reducing treatment costs and accelerating patient recovery times.
IceCure Medical Ltd. (NASDAQ: ICCM) has secured significant regulatory and intellectual property milestones for its next-generation cryoablation technology, positioning the company to expand its minimally invasive tumor treatment platform. The Israeli medical device developer received a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative cryoprobe technology and regulatory approval in Israel for its XSense System across multiple medical specialties.
Patent Innovation Enhances Cryoprobe Safety
The newly patented cryoprobe technology introduces a novel method for safely extracting the device after tissue freezing during cryoablation procedures. The invention integrates a heater, temperature sensor, and controlled gas pulses into the cryoprobe's tip, enabling precise estimation and management of the device's external surface temperature even while embedded in frozen tissue.
"Our industry-leading liquid-nitrogen-based cryoablation platform has been further advanced with this latest invention, a cryoprobe technology," stated IceCure's Chief Executive Officer, Eyal Shamir. "This new cryoprobe technology, which is integrated in our next-generation XSense system, further reduces any potential risk of tissue trauma as the cryoprobe is extracted from the patient at the end of the short, minimally invasive outpatient procedure."
The patented technology is designed to be compatible with a wide range of XSense System cryoprobe types, providing a versatile solution for multiple clinical scenarios.
Regulatory Approval Expands Treatment Options
IceCure received regulatory approval from Israel's Ministry of Health Medical Device Division (AMAR) for its XSense System and CryoProbes. The approval covers a comprehensive range of indications including general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, ENT (ear, nose, throat), gynecology, oncology (including benign and malignant breast tumors), proctology, and urology.
The XSense System had previously received regulatory clearance from the U.S. Food and Drug Administration in mid-2024 for all indications already approved for the company's flagship ProSense system.
"We believe that this latest regulatory approval for our next-generation cryoablation system reaffirms IceCure's leadership position in liquid-nitrogen based cryoablation," Shamir noted. "The minimally invasive cryoablation option that we offer across a broad range of indications can de-escalate cancer care, reduce treatment costs for payers, and accelerate recovery time for patients."
Clinical Focus on Breast Cancer Treatment
The company expressed particular enthusiasm about the breast cancer indication approval in Israel. "We are particularly pleased with the breast cancer indication approval in Israel, as we believe the growing body of evidence on cryoablation as a minimally invasive option for breast cancer supports accelerated commercial adoption," Shamir added.
According to the company, there is an abundance of data, much from independent studies, showing that minimally invasive cryoablation procedures with the ProSense system have resulted in improved patient experiences with excellent medical outcomes.
Technology Platform and Clinical Applications
IceCure's platform technology, including both the ProSense and XSense Cryoablation Systems, provides minimally invasive treatment options to destroy tumors by freezing them. The systems harness liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver tumors.
The cryoablation systems are designed to enhance patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With their transportable design and liquid nitrogen utilization, both ProSense and XSense systems enable fast and convenient office-based procedures for breast tumors.
IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems with primary focus areas including breast, kidney, bone, and lung cancer. The company's flagship ProSense system is currently marketed and sold worldwide for cleared and approved indications in the U.S., Europe, and Asia.